In the current study, we used the γ-H2AX + 53BP1 DSB focus assay to investigate the time- and dose-dependency of DNA DSB induction and repair in blood leucocytes of prostate cancer patients during their first therapy with 177Lu-PSMA. Here, FOLH1 is linked to prostate carcinoma.